Increased prevalence of influenza B/victoria lineage viruses during early stages of the 2015 influenza season in new South Wales, Australia: Implications for vaccination and planning

Eurosurveillance

Volumn 20, Issue 31, 2015, Pages

  Jennings, Z ^a   Carter, I ^a   McPhie, K ^a   Kok, J ^a,b,c   Dwyer, D E ^a,b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; AUSTRALIA; CELL LINEAGE; HUMAN; IMMUNE RESPONSE; INFLUENZA B; NONHUMAN; PREVALENCE; TREATMENT PLANNING; VACCINATION; VERTICAL TRANSMISSION; CHILD; DISEASE OUTBREAKS; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFANT; INFLUENZA B VIRUS; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MALE; PRESCHOOL CHILD; SEASON;

AUSTRALIA; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NEW SOUTH WALES; PREVALENCE; SEASONS; VACCINATION;

EID: 84938777022     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2015.20.31.21201     Document Type: Article

References (21)

1. New South Wales (NSW) Ministry of Health (MoH). NSW Health Influenza Surveillance Report. Week 28: 6 to 12 July 2015. Sydney: NSW MoH; 2015. Available from: http://www.health.nsw.gov.au/Infectious/Influenza/Documents/2015/weekending-12072015.pdf
2. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the northern hemisphere 2015-16 influenza season and development of candidate vaccine viruses for pandemic preparedness. Geneva: WHO; 2015. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/201502_qanda_recommendation.pdf?ua=1
3. World Health Organization (WHO). Influenza update No 242. Geneva: WHO; 27 Jul 2015. Available from: http://who.int/influenza/surveillance:monitoring/updates/2015_07_27_surveillance:update_242.pdf
4. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, summary Europe, May 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-May-2015.pdf
5. Appiah GD, Blanton L, D’Mello T, Kniss K, Smith S, Mustaquim D, et al.; Centers for Disease Control and Prevention (CDC). Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2015;64(21):583-90. PMID:26042650
6. Li WC, Shih SR, Huang YC, Chen GW, Chang SC, Hsiao MJ, et al. Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J Clin Virol. 2008;42(1):45-51. http://dx.doi.org/10.1016/j.jcv.2007.11.026 PMID:18325832
7. Paddock CD, Liu L, Denison AM, Bartlett JH, Holman RC, Deleon-Carnes M, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis. 2012;205(6):895-905. http://dx.doi.org/10.1093/infdis/jir861 PMID:22291193
8. van der Vries E, Ip DK, Cowling BJ, Zhang JD, Tong X, Wojtowicz K, et al. Outcomes and susceptibility to neuraminidase inhibitors in individuals infected with different influenza B lineages: the Influenza Resistance Information Study. J Infect Dis. 2015. pii: jiv375. PMID: 26160744
9. Farrukee R, Leang SK, Butler J, Lee RT, Maurer-Stroh S, Tilmanis D, et al. Influenza viruses with B/Yamagata- and B/Victorialike neuraminidases are differentially affected by mutations that alter antiviral susceptibility. J Antimicrob Chemother. 2015;70(7):2004-12. PMID:25786478
10. World Health Organization Collaborating Centre for Reference and Research on Influenza (VIDRL). Type/subtype/lineage of samples analysed at the Centre. Samples collected 1 January - 31 May 2015. Melbourne: VIDRL; 2015. [Accessed 28 Jul 2015]. Available from: http://www.influenzacentre.org/surveillance:subtypes.htm
11. Bodewes R, de Mutsert G, van der Klis FR, Ventresca M, Wilks S, Smith DJ, et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin Vaccine Immunol. 2011;18(3):469-76. http://dx.doi.org/10.1128/CVI.00396-10 PMID:21209157
12. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza -- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60(1):1-24. PMID: 21248682
13. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81-8. http://dx.doi.org/10.4161/hv.8.1.17623 PMID:22252006
14. Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207(12):1878-87. http://dx.doi.org/10.1093/infdis/jit091 PMID:23470848
15. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis. 2013;13(1):343. http://dx.doi.org/10.1186/1471-2334-13-343 PMID:23883186
16. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30(11):1993-8. http://dx.doi.org/10.1016/j.vaccine.2011.12.098 PMID:22226861
17. You JH, Ming WK, Chan PK. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014;14(1):618. http://dx.doi.org/10.1186/s12879-014-0618-9 PMID:25420713
18. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):153. http://dx.doi.org/10.1186/1741-7015-11-153 PMID:23800265
19. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529-40. http://dx.doi.org/10.1093/infdis/jiu647 PMID:25406334
20. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE. 2014;9(3):e92153. http://dx.doi.org/10.1371/journal.pone.0092153 PMID:24667168
21. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126-37. http://dx.doi.org/10.1093/infdis/jiu048 PMID:24446529